ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Risk factors for skeletal-related events in patients with stage IV lung adenocarcinoma and bone metastases receiving denosumab: a retrospective cohort analysis.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify independent risk factors for skeletal-related events(SREs) during denosumab treatment in patients with bone-metastatic stage IV lung adenocarcinoma by integrating multidimensional clinical parameters, thereby providing an evidence-based foundation for risk stratification and targeted management.
methodsIn this retrospective cohort study, patients with stage IV lung adenocarcinoma and radiologically confirmed bone metastases diagnosed at Xuanhan County People's Hospital between July 2021 and December 2023 were enrolled. All patients received standardized denosumab therapy (120 mg subcutaneously every 4 weeks ± 7 days). Baseline demographic, laboratory, and treatment response data were extracted from the electronic medical record system. Univariate analyses were used to screen candidate variables, followed by multivariate logistic regression to identify independent predictors. Model fit was assessed using the Hosmer-Lemeshow test.
resultsA total of 111 patients were included (median age, 65.5 years; 50.45% male). During follow-up, 27 patients (24.3%) experienced SREs. Multivariate analysis identified a prior history of bisphosphonate use as an independent protective factor against SREs (odds ratio [OR], 0.191; 95% confidence interval [CI], 0.049-0.741 P = 0.017), while Pretreatment hypocalcemia and smoking were both significantly associated with increased risk.
conclusionsThis study is the first to demonstrate in a county-level hospital cohort that a history of bisphosphonate use serves as an independent protective factor against SREs during denosumab treatment, while Pretreatment hypocalcemia and smoking history significantly increase SREs risk. These findings provide critical evidence for individualized management of stage IV lung adenocarcinoma patients with bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.